Chiasma Inc is a biopharmaceutical company that focuses on improving the lives of patients who face challenges associated with existing treatments for their rare and debilitating diseases. Its product candidate includes octreotide capsule which has completed Phase III clinical trial and it is being developed for the potential treatment of acromegaly, a rare, debilitating disease. The company offers its products in the United States and the European Union.Chiasma Inc is a biopharmaceutical company which focuses on improving the lives of patients who face challenges associated with existing treatments for their rare and debilitating diseases.